Background: The catalytic domain of ADAMTS13 possesses one Zn 2+ and up to three
| INTRODUC TI ON
The plasma metalloprotease ADAMTS13 is the key physiologic regulator of multimeric von Willebrand factor (VWF). [1] [2] [3] Enzyme deficiencies due to mutations in the ADAMTS13 gene or to inhibition by autoantibodies result in an excess of platelet aggregation and disseminated VWF/platelet-rich thrombus formation, which are cardinal features of thrombotic thrombocytopenic purpura (TTP).
2,4-6
The catalytic metalloprotease domain of ADAMTS13 possesses a number of predicted metallic cation binding sites. These include an essential Zn 2+ coordination site in the active site, with the consensus sequence HEXXHXXGXXHD harboring three critical histidine residues, 7 and three putative Ca 2+ binding sites. Based on mutational
Essentials
• Thrombotic thrombocytopenic purpura therapy involves ADAMTS13-containing citrated human plasma.
• ADAMTS13 stability and structure in the presence of citrate or heparin were assessed.
• ADAMTS13 activity decreased in citrated but not heparinized plasma.
• Zn 2+ stabilizes ADAMTS13 at 37°C and prevents irreversible activity loss.
F I G U R E 1 Instability of ADAMTS13 normal human plasma (NHP) at physiologic temperature (37°C) is caused by citrate. A, ADAMTS13 activity was measured in citrated pooled NHP and in a purified system (recombinant human ADAMTS13) at room temperature (RT) and at 37°C at 0, 0.5, 1, 2, 5, and 24 h of incubation. ADAMTS13 activity in NHP decreased at 37°C but not at room temperature in a time-dependent manner. B, ADAMTS13 activity was measured in heparinized pooled NHP with or without citrate (0.38% w/v) at room temperature and at 37°C at 0, 1, 2, 4, 6, and 24 h of incubation. ADAMTS13 activity in heparinized NHP was maintained at both temperatures, whereas the addition of citrate caused a gradual loss of activity at 37°C. C, Citrated pooled NHP plus 10 U/mL heparin as anticoagulant was incubated in the presence of increasing concentrations of Ca 2+ at 37°C for 24 h, and ADAMTS13 activity was measured at 0, 1, 2, 5, and 24 h of incubation. ADAMTS13 activity was fully maintained at a concentration of 5 mmol/L Ca 2+ or higher. D, Citrated pooled NHP plus 10 U/mL heparin was incubated in the presence of increasing concentrations of Zn 2+ at 37°C for 24 h, and ADAMTS13 activity was measured at 0, 1, 2, 5, and 24 h. ADAMTS13 activity was fully maintained at a concentration of 0.5 mmol/L Zn 2+ or higher. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as compared with control (A: citrated NHP, RT; B: heparinized NHP, RT; C: citrated NHP + 10 mmol/L CaCl 2 , 37°C; D: citrated NHP + 2 mmol/L ZnCl 2 , 37°C) analyses, only a single site seems to be important for enzyme activity. 8 The The impact of citrate on enzyme stability is less clear.
ADAMTS13 activity was reported to be stable in citrated NHP at room temperature for up to 48 hours, 18 and to be only very slowly inactivated at 37°C, with a half-life longer than 1 week. 19 On the other hand, cleavage of denatured multimeric VWF by citrated NHP was shown to be complete at 22°C and 4°C and only partial at physiologic temperature. 20 Similarly, Kraisin et al found a negative influence of physiologic temperature on the stability of ADAMTS13 activity in citrated normal plasma, with a half-life ranging between 24 and 48 hours. 21 Here we explored the temperature-dependent stability of ADAMTS13 using various sources of NHP and recombinant human ADAMTS13 (rADAMTS13) in different experimental setups. We further aimed to identify the cause of the observed instability in the presence of citrate at physiological temperature by determining whether enzyme inactivation correlates with reduced metal ion binding and structural disintegration. Citrated NHP + 10 U/mL heparin 37°C
| ME THODS

| Sources of ADAMTS13
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| Stability testing of ADAMTS13 activity
All samples of a test series were measured for ADAMTS13 activity using the synthetic fluorogenic FRETS-VWF73 peptide substrate (Peptanova GmbH, Sandhausen, Germany), as previously described. 22 The 
| Analysis of ADAMTS13 metal ion binding by size exclusion chromatography inductively coupled plasma mass spectrometry
The SEC-ICP-MS analysis was carried out essentially as described previously. 23 An Ultimate 3000 ×2 Dual Titanium HPLC system (Thermo Fisher Scientific, Karlsruhe, Germany) controlled by Chromeleon 6.8 software was used for the size exclusion separation. For elemental detection, the system was combined with an Elan 6100 DRCII quadrupole ICP-MS from Perkin-Elmer-Sciex (Toronto, Canada 
| Analysis of ADAMTS13 conformation by dynamic light scattering and Fourier-transformed infrared spectroscopy
Dynamic light scattering (DLS) was performed using a Malvern NanoZetasizer ZS (Malvern Instruments Ltd, Malvern, UK) and a Haake Rheostress 1 (Thermo Fisher Scientific) equipped with a cone with a 60-mm diameter/0.5° angle essentially as described previously. 24 The protein's angle was set to 173° backscatter to measure its size.
Fourier-transformed infrared (FTIR) spectroscopy was performed using the FTIR spectroscope TENSOR 27 (Bruker Optik GmbH, Ettlingen, Germany) equipped with a BioATR II cell working in attenuated total reflection mode essentially as described previously. 25 The secondary structure (percent α-helix and β-sheet) of the protein was calculated by the evaluation software OPUS 6.0 (Bruker Optik GmbH), which contains a database of approximately 40 proteins of known secondary structure.
| Statistical evaluation
All calculations were performed using GraphPad (7.03) software.
Graphs were subjected to spline or point-to-point regression and
analyzed by two-way ANOVA.
| RE SULTS AND D ISCUSS I ON
| Stability of ADAMTS13 is compromised by citrate at physiologic temperature (37°C)
The temperature-dependent stability of ADAMTS13 in plasma was initially assessed by measuring FRETS-VWF73 fluorogenic activity in pooled citrated NHP incubated at room temperature and at 37°C. While ADAMTS13 activity was maintained over the entire incubation period of 24 hours at room temperature, a time-dependent activity reduction was observed at 37°C. In a purified system using recombinant ADAMTS13 however, the enzyme's activity was maintained regardless of the temperature ( Figure 1A ). In NHP anticoagulated with heparin, ADAMTS13 activity was also stable over 24 hours at 37°C ( Figure 1B) ; however, addition of citrate to the heparinized NHP caused a time-dependent drop in ADAMTS13 activity,
The citrate-dependent activity drop correlates with a loss of ADAMTS13's bound Zn
2+
. A, Demonstration of (substoichiometric quantities of) Zn 2+ bound to ADAMTS13. Shown is a representative chromatogram of purified recombinant human ADAMTS13 obtained via size exclusion chromatography inductively coupled plasma mass spectrometry (SEC-ICP-MS). Dynamic reaction cell technology was applied utilizing oxygen as reaction gas, enabling the interference-free measurement of sulfur as SO + (m/z = 48). Zn 
| Destabilization of ADAMTS13 by citrate at physiologic temperature is irreversible
We next tested whether the addition of Ca 2+ and/or Zn 2+ to citrated NHP that had been incubated at 37°C for 24 hours would restore ADAMTS13 activity (Figure 2 ). ADAMTS13 activity was monitored for 8 days, but neither Ca 2+ ( Figure 2A ) nor Zn 2+ ( Figure 2B ) alone nor the mixture of both metal ions ( Figure 2C ) fully restored enzyme activity. Nonetheless, stabilization of the residual activity was achieved when compared with the untreated citrated NHP sample.
Activity remained stable in control samples where the addition of metal ions occurred at the zero-hour time point. These data suggested that, at physiologic temperature, citrate slowly depleted ADAMTS13 of divalent cations, most likely Ca 2+ and Zn
2+
, which resulted in inactivation of the enzyme.
| Citrate promotes ADAMTS13 destabilization by the removal of Zn
2+
To monitor potential changes in metal ion binding with the addition of citrate directly, we determined the amount of bound Ca
and Zn 2+ in purified rADAMTS13 using SEC-ICP-MS ( Figure 3A) . The resulting chromatogram revealed congruent sulfur and Zn 2+ peaks consistent with ADAMTS13's essential Zn 2+ binding site in its active center. No Ca 2+ peak was discernible at the retention time of the sulfur and Zn 2+ peaks, even at 100× magnification. This is likely because all the loosely associated Ca 2+ was removed during the purification process, as observed previously. 8 Calculation of the zinc-to-sulfur stoichiometric ratio, using Cu/Zn-SOD as reference for determining the molar 66 Zn to 32 S 16 O intensity ratio of the instrument, 23 revealed a zinc loading density for rADAMTS13 that fluctuated between the measurements from 25% to 40%. These data suggest that the active site-associated Zn 2+ is also not as tightly bound as the metal ions in the dismutase, which maintains its activity even under denaturing conditions.
26
A stability study focusing on changes in rADAMTS13's molar ratio of Zn 2+ to protein in dependence of citrate and temperature showed a quick drop at 37°C in the presence of citrate, but not at 20°C or in the absence of citrate ( Figure 3C,E) . The kinetics of The citrate-dependent activity drop correlates with changes in the higher-order structure of ADAMTS13. Recombinant human ADAMTS13 was incubated in the presence or absence of citrate (0.38% w/v) and increasing concentrations of Ca 2+ at 4°C and 37°C for up to 24 h. At 0, 5, and 24 h, samples were analyzed for the activity of the enzyme, A, as well as its structural integrity, using dynamic light scattering (hydrodynamic diameter in nanometers) and Fourier-transformed infrared spectroscopy (α-helix and β-sheet content). In the presence of citrate at physiologic temperature, the drop in ADAMTS13 activity was accompanied by an increase of the enzyme's hydrodynamic diameter, B, a drop in its α-helical content, C, and a slight increase in its β-sheet content, D. Calculated is the average of three runs per sample. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as compared to control (A-D: rADAMTS13 without citrate, 4°C) the decrease coincided with the reduction of ADAMTS13 activity ( Figure 3B,D) , demonstrating a close relationship between these two parameters.
| Citrate-triggered Zn
2+ depletion at physiologic temperature results in a destabilization of ADAMTS13's higher-order structure
Since the observed ADAMTS13 activity decline was not due to proteolysis (evidenced by SDS PAGE of rADAMTS13 and addition of protease inhibitors to citrated NHP; not shown), we studied the protein's structural integrity by measuring its hydrodynamic diameter using DLS. Diameters remained in a narrow range for all conditions and time points where ADAMTS13 activity was not reduced ( Figure 4A,B) . In contrast, a marked increase in the diameter was noted for all four samples with a low residual activity (<20%). Since such a size increase is typical for proteins that transition into a lessordered structure, 27 a correlation between the loss of activity and structural integrity of ADAMTS13 could be hypothesized.
To substantiate this correlation, the change in percentage of secondary structural elements in ADAMTS13 was followed by FTIR spectroscopy. The citrate-dependent decrease in ADAMTS13 activity at 37°C was indeed associated with a marked reduction of α-helical content ( Figure 4C ) and a slight increase in β-sheet content ( Figure 4D ), typical for transitions into less-ordered protein structures. 
| Novel insights on ADAMTS13 structurefunction relationship
This study shows that zinc is not only required for maintaining the catalytic activity of ADAMTS13 but also for stabilizing its conformation. , demonstrating that ADAMTS13 stability was irreversibly compromised, perhaps because dimers or aggregates had already formed. To understand these rearrangements better, elucidation of ADAMTS13's metalloprotease domain structure and its dynamics upon citrate-dependent demetalation at 37°C will be required.
| Clinical relevance
Citrate is a commonly used anticoagulant to arrest the clotting cascade through chelation of Ca
2+
. 29 The effect on ADAMTS13 stability reported here should be considered when measuring inhibitory anti-ADAMTS13 antibodies in plasma samples from pa- 
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